

India supplying drugs, vaccines, and devices to over 200 countries: DCGI

Speaking at the 19th International Conference of Drug Regulatory Authorities (ICDRA) in the national capital, Dr Raghuvanshi said that, "India is supplying drugs, vaccines, and medical devices to more than 200 countries across the world."



New Delhi: India's pharmaceutical sector continues to cement its position as a global leader, with Drug Controller General of India (DCGI) Dr Rajeev Raghuvanshi highlighting the country's significant contributions to

global healthcare.

Speaking at the 19th International Conference of Drug Regulatory Authorities (ICDRA) in the national capital, Dr Raghuvanshi, the DCGI, highlighted the significant contributions of India to global healthcare. He stated, "India is supplying drugs, vaccines, and medical devices to more than 200 countries across the world."

Dr Raghuvanshi underscored the breadth of the nation's impact, emphasizing India's role as a key player in ensuring the availability of essential medical products globally. This assertion not only reflects India's robust pharmaceutical sector but also its commitment to advancing health outcomes around the world.

Furthermore, he said, "11 countries have already recognised the Indian Pharmacopoeia as their standard, signifying the growing international trust in India's regulatory framework and quality control measures."

In his address he also asserted that, “In an era where technological advancements are driving innovation in healthcare, India is also playing a key role in global clinical research. Now we (Indian drug regulators) are approving an average of 100 global clinical trials every year for the last couple of years.”

With respect to introduction of new therapeutic methods, he said, “India’s regulatory system, led by the National Regulatory Authority (NRA) is reviewing and has approved the latest technology-based products like CAR T-cell therapy, mRNA vaccines, and software as medical devices, which shows that we are going through continuous upgradation.”

News Source:

<https://pharma.economictimes.indiatimes.com/news/policy-and-regulations/bayer-must-pay-78-million-in-latest-roundup-cancer-trial-jury-finds/114133214>